Johnson & Johnson Inc. (JNJ) – Get the report it posted a stronger-than-expected gain in the fourth quarter on Tuesday and said it would provide “an update” on its progress in vaccine development “soon.”
Johnson & Johnson said adjusted earnings for the three months ending December were set at $ 1.86 cents a share, down 1.1% from the same period last year, but down four cents. consensus on the street. The group’s revenue, Johnson & Johnson said, rose 8.3 percent to $ 22.5 billion, again beating analysts’ estimates of $ 21.67 billion.
Consumer brands and the healthcare group said they see an adjusted revenue growth of 16.4% for 2021, or $ 9.40 to $ 9.60 per share, along with an increase in sales of about 8 percent. , 8%.
“Our outstanding performance throughout the year reflects the continued confidence of patients, physicians, customers and consumers in our life-enhancing products and medicines, especially throughout the COVID-19 pandemic,” said CEO Alex Gorsky.
“I am incredibly proud of our Johnson & Johnson teams around the world for going beyond and beyond to meet the needs of stakeholders. “Our efforts and our commitment to families around the world as the largest basic health care company have allowed us to lead the fight against COVID-19,” he added. We continue to make progress on our COVID-19 vaccine candidate and look forward to sharing details from our Phase 3 study soon. Johnson & Johnson was built for times like these and I am extremely confident in our ability to deliver sustainable value and continuous innovation in 2021 and beyond. ”
Johnson & Johnson shares were 3.6% higher at early trading immediately after launching gains to change hands at $ 171.45 each, extending the six-month earnings of the stock to about 15%.
Pharmaceutical sales drive the group’s earnings, up 16.3 percent from $ 12.27 billion last year, driven by solid revenues from Stelara’s treatment for immune-mediated inflammatory diseases and Imbruvica, its blood cancer drug.
This offset a 0.7% drop in medical device revenue to $ 6.59 billion and a modest 1.4% gain in consumer health sales to 3.62. billions of dollars.